
MediciNova reports encouraging Phase 2 trial results for MN-001 in liver disease and updates on ALS drug MN-166 progress
MediciNova announced positive signals from its Phase 2 trial of MN-001 (tipelukast) for nonalcoholic fatty liver disease and hypertriglyceridemia in type 2 diabetes, showing significant improvements in HDL cholesterol and early triglyceride reduction...





